Cargando…

Efficacy of Dulaglutide Expanded Doses by Baseline A1C Categories: Post Hoc Analysis of AWARD-11

The AWARD-11 trial demonstrated the safety and efficacy of dulaglutide (DU) once weekly doses of 3 mg and 4.5 mg compared to DU 1.5 mg in patients with type 2 diabetes (T2D) inadequately controlled with metformin monotherapy. This exploratory post hoc analysis of AWARD-11 assessed the effect of dula...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frias, Juan Pablo, Bonora, Enzo, Cox, David A, Kwan, Anita, Raha, Sohini, Bethel, Angelyn, Malik, Raleigh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Diabetes Mellitus and Glucose Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090394/ http://dx.doi.org/10.1210/jendso/bvab048.678

Ejemplares similares

Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD‐11
por: Frias, Juan P., et al.
Publicado: (2021)

OR26-08 Efficacy and Safety of Higher Dulaglutide Doses (3.0 MG and 4.5 MG) When Added to Metformin in Patients With Type 2 Diabetes: A Phase 3, Randomized, Double-Blind, Parallel ARM Study (Award-11)
por: Frias, Juan Pablo, et al.
Publicado: (2020)

Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11
por: Van, Joanna, et al.
Publicado: (2021)

Necrotizing Pancreatitis Secondary to Dulaglutide Use
por: Bhat, Salman Zahoor, et al.
Publicado: (2021)

Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD‐11 trial
por: Frias, Juan P., et al.
Publicado: (2021)

OR30-06 Assessment of Dulaglutide Safety in Older Patient Populations in Rewind
por: Konig, Manige, et al.
Publicado: (2020)

Comparing Quality of Life in Type 2 Diabetic Patients Using Dulaglutide and Liraglutide
por: Ghosh, Aneesh
Publicado: (2021)

Anaphylactic Reaction to Dulaglutide: A Glucagon Like Peptide- 1 Receptor Agonist
por: Quadri, Hamza, et al.
Publicado: (2021)

MON-681 Dulaglutide Commonly Known as Trulicity; An Anti-Diabetic Medication Causing Small Bowel Obstruction
por: Gandhi, Ankita, et al.
Publicado: (2020)

Long-Term Effectiveness and Safety of Once Weekly Dulaglutide as Add-on to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
por: Mirabelli, Maria, et al.
Publicado: (2021)

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)
por: Frias, Juan P., et al.
Publicado: (2021)

PSUN270 Magnified Risk of Pancreatitis by GLP-1: A Case of Necrotizing Pancreatitis in a Patient on Dulaglutide with Baseline Elevated Triglycerides
por: Yau, Alice, et al.
Publicado: (2022)

Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD‐11
por: Bonora, Enzo, et al.
Publicado: (2021)

FRI646 Dulaglutide-induced Acute Liver Injury - A Case Report
por: Shahid, Maham, et al.
Publicado: (2023)

OR22-2 Exposure to Hypoglycemia in Older Adults with Type 1 Diabetes: Baseline Characteristics Using Continuous Glucose Monitoring Data
por: Carlson, Anders, et al.
Publicado: (2019)

MON-645 Association of Baseline Cardio-Metabolic Parameters on the Treatment Effects of Empagliflozin When Added to Metformin in Patients with T2D
por: Inzucchi, Silvio E, et al.
Publicado: (2020)

PSUN241 A Case of Dulaglutide-Induced Acute Pancreatitis in a Diabetic Patient – A Case Report
por: Abdelmasih, Randa, et al.
Publicado: (2022)

Once Weekly Basal Insulin Fc (BIF) is Safe and Efficacious in Patients with Type 2 Diabetes Mellitus (T2DM) Previously Treated With Basal Insulin
por: Frias, Juan Pablo, et al.
Publicado: (2021)

FRI638 Glycemic And Cost Outcomes In Hispanic/Latino People With Type 2 Diabetes Initiating Dulaglutide Or Basal Insulin In The US
por: Hoog, Meredith, et al.
Publicado: (2023)

OR28-4 Efficacy and Safety of Tirzepatide Versus Semaglutide in a Hispanic or Latino Population: A Prespecified Subgroup Analysis of SURPASS-2
por: Benneyworth, Brian D, et al.
Publicado: (2022)

Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD‐11 study
por: Cox, David A., et al.
Publicado: (2022)

MON-LB024 Episodic Hypoglycemia in Non-Diabetics: Differentiating Distressing from Deadly
por: Windham, Mary, et al.
Publicado: (2019)

MON-LB028 Comparing Cardiovascular Effects of GLP-1 Agonists in a Real World Setting
por: Wallia, Amisha, et al.
Publicado: (2019)

MON-158 Association between Famine Exposure in Early Life with Insulin Resistance and β-cell Dysfunction in Adulthood
por: Wang, Yuying, et al.
Publicado: (2019)

MON-159 Increased Gluconeogenesis and Lower Glycogenolysis in Patients with Non-Selective Compared Selective Insulin Resistance
por: Sekizkardes, Hilal, et al.
Publicado: (2019)

MON-164 The Non-insulin-based METS-IR Index Combined With Liver Transaminases Improves Prediction Of Fatty Liver And Fibrosis
por: Bello-Chavolla, Omar, et al.
Publicado: (2019)

MON-162 Hepatic DNA Damage Induced by ENDS Is Associated with Decreased Levels of NAD+
por: Espinoza-Derout, Jorge, et al.
Publicado: (2019)

MON-150 Phone Call Reminders and Mobile Health Apps: Do They Help Our Diabetic Patients?
por: Lu, Kevin, et al.
Publicado: (2019)

MON-182 Adaptable Amperometric Biosensor Platforms for the Diagnosis of Endocrine Disorders
por: Labban, Najwa, et al.
Publicado: (2019)

MON-129 An Unusual LMNA Mutation Causing a Complex Phenotype: When the Genetic Diagnosis Uncovers Novel Features
por: Andrade, Natália, et al.
Publicado: (2019)

MON-178 Vitamin D Treatment of Patients with Type 1 Diabetes Reduces RORy, FoxP3 and CD4 Gene Expression in T Helper Cells
por: Penna-Martinez, Marissa, et al.
Publicado: (2019)

MON-154 Abnormal Glucose Homeostasis in Spinal Muscular Atrophy (SMA) Leading to a Transient Episode of Diabetic Ketoacidosis (DKA)
por: Hossain, Sabina, et al.
Publicado: (2019)

MON-149 The Impact of Diabetes Educational Videos in Diabetes Attitudes in a Brazilian Population
por: Zappala, Renata, et al.
Publicado: (2019)

MON-177 The Effect of Gluten Protein Components on Type 1 Diabetes and the Viability of Treatment with Antioxidants
por: Goodman, Miri
Publicado: (2019)

MON-151 Hypertriglyceridemia and Acute Pancreatitis Leading to Ketoacidosis in a Patient with Type 2 Diabetes
por: Fishel, Heather, et al.
Publicado: (2019)

MON-189 Glycemic Control and the Presence of Complications in Glycogen Storage Disease Type I: Results from the Swiss Registry
por: Kaiser, Nathalie, et al.
Publicado: (2019)

MON-171 Diabetics' Perceptions about Insulin Are Major Barriers to Its Early Initiation: A Cross-Sectional Study
por: Arshad, Iqra, et al.
Publicado: (2019)

MON-124 Antibody-Mediated Extreme Insulin Resistance: The Importance of Pre-Treatment Screening
por: Mosaferi, Tina, et al.
Publicado: (2019)

MON-140 A Case of Gestational Starvation Ketoacidosis in a Diabetic Mother Mimicking the Presentation of Acute Coronary Syndrome
por: Ibrahim, Dina, et al.
Publicado: (2019)

MON-188 Characterization and Categorization Based on Genotype-Biochemical Phenotype Association in Fructose-1,6-Bisphosphatase Deficiency
por: Sakuma, Ikki, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2j864vnomq3phc43g9vc13fb2i